Celgene and AnaptysBio team up to develop antibodies

04/11/2012 | Pharmaceutical Business Review Online

AnaptysBio and Celgene agreed to jointly develop antibodies against oncology and inflammation-related targets using the former's SHM-XEL platform. Celgene will get worldwide development and commercialization rights to antibodies discovered by its partner. AnaptysBio will receive an upfront fee, plus milestone payments and sales royalties.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief: